Clinical trial
Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in…
NCT00444314 · CASI Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00444314 |
|---|---|
| Title | Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma |
| Official title | Phase II Study of 2-Methoxyestradiol Nanocrystal Colloidal Dispersion Alone and in Combination With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma Progressing on Sunitinib Malate |
| Lead sponsor | CASI Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Renal Cell Carcinoma |
| Intervention type | Drug |
| Interventions | Panzem® NCD, Sunitinib Malate |
| Enrollment | 82 |
| Start date | Feb 1, 2007 |
| Primary completion | Dec 1, 2008 |
| Completion | Oct 1, 2009 |
| First posted | Mar 7, 2007 |
| Last update posted | Aug 4, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: